Current Report Filing (8-k)
September 18 2017 - 11:08AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): September 5, 2017
RICH
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
NEVADA
|
|
000-54767
|
|
46-3259117
|
(State
or other jurisdiction of
incorporation or organization)
|
|
Commission
file number
|
|
(IRS
Employer
Identification
No.)
|
9595
Wilshire Blvd, Suite 900
Beverly
Hills, CA 90212
(Address
of principal executive offices)
(424)
230-7001
(Registrant’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
◻
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
◻
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
◻
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
◻
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 4.01
|
Changes In Registrant’s Certifying Public Accountant
|
|
(a)
|
Dismissal of KLJ & Associates, LLP (“KLJ”).
|
On September 5, 2017 (the “Dismissal
Date”), the Board of Directors of the Company determined to dismiss KLJ as its independent registered public accounting firm.
The report of KLJ on the audited financial
statements of the Company for the fiscal years ended March 31, 2017 and March 31, 2016 did not contain any adverse opinion or disclaimer
of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles, except a going concern qualification
on the Company’s financial statements for the fiscal years ended March 31, 2017 and March 31, 2016.
During the Company’s two most recent
fiscal years, the subsequent interim periods thereto, and through the Dismissal Date, there were no disagreements (as defined in
Item 304 of Regulation S-K) with KLJ on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedure, which disagreements, if not resolved to the satisfaction of KLJ, would have caused it to make reference in
connection with its opinion to the subject matter of the disagreement. Further, during the Company’s two most recent
fiscal years, the subsequent interim periods thereto, and through the Dismissal Date, there were no reportable events (as defined
in Item 304(a)(1)(v) of Regulation S-K).
The Company provided KLJ with a copy of this
Report prior to its filing with the Securities and Exchange Commission (the “SEC”) and requested KLJ to furnish the
Company with a letter addressed to the SEC, stating whether or not it agrees with the statements made above and, if not, stating
the respects in which they do not agree. A copy of such letter is filed as an exhibit to this report.
|
(b)
|
Engagement of Anton & Chia, LLP (“Anton & Chia”)
|
On September 5, 2017 (the “Engagement
Date”), the Company’s Board of Directors approved the appointment of Anton & Chia as the Company’s independent
registered public accounting firm. During the Company’s two most recent fiscal years, the subsequent interim periods thereto,
and through the Engagement Date, neither the Company nor anyone on its behalf consulted Anton & Chia regarding either (1) the
application of accounting principles to a specified transaction regarding the Company, either completed or proposed, or the type
of audit opinion that might be rendered on the Company’s financial statements; or (2) any matter regarding the Company that
was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions to Item 304
of Regulation S-K) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
The exhibits listed in the following Exhibit Index are filed as
part of this Current Report on Form 8-K.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
RICH
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
Dated:
September 15, 2017
|
|
|
|
By:
|
|
/s/ Ben
Chang
|
|
|
|
|
|
|
|
|
Ben
Chang
Chief
Executive Officer
|